Showing 4161-4170 of 9891 results for "".
- Takeda’s TYK2 Blocker Impresses in Phase 2b PsO Studyhttps://practicaldermatology.com/news/takedas-tyk2-blocker-impresses-in-phase-2b-pso-study/2461622/Takeda’s TYK2 inhibitor TAK-279 performed well in a Phase 2b study of patients with moderate-to-severe plaque psoriasis. TAK-279 was developed by Nimbus Therapeutics and owned by Takeda. The new findings were presented at the 2023 American Academy of Dermatology (AAD) An
- Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL Studyhttps://practicaldermatology.com/news/timber-pharmaceuticals-announces-publication-of-sub-analysis-of-phase-2b-control-study/2461620/Timber Pharmaceuticals announced the online publication of a sub-analysis of the Phase 2b CONTROL study, which is evaluating TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, in subjects 9 years of age and older with moderate t
- Cetaphil Celebrates Sensitive Skin with a Month of Skin Science Educationhttps://practicaldermatology.com/news/cetaphil-celebrates-sensitive-skin-with-a-month-of-skin-science-education/2461610/Cetaphil is ringing in the 2nd Annual Sensitive Skin Awareness initiative globally with a month of skin science education. Activating under the brand's campaign, "We Do Skin. You Do You," the global science effort will arm consumers with guidance on how to i
- BeautyHealth Acquires SkinStylushttps://practicaldermatology.com/news/beautyhealth-acquires-skinstylus/2461579/The Beauty Health Company is set to acquire SkinStylus, a US Food and Drug Adminstrayion -cleared microneedling device. The agreement represents a key step forward in BeautyHealth’s portfolio build-up strategy. Upon successful integration of SkinStylus into the BeautyHealth
- Study: Plugging Immune Cell Leakage from Tumors Could Improve MelanomaTreatmenthttps://practicaldermatology.com/news/study-plugging-immune-cell-leakage-from-tumors-could-improve-melanomatreatment/2461578/The number of specialized immune cells available for fighting skin cancer double when a new treatment blocks their escape from melanoma tumors, according to new research out of NYU Langone Health’s Perlmutter Cancer Center Combining a chemical blocker of immune cell exit with
- Neauvia Scores CE Marking Under the European Union’s New MDR for Facial Dermal Filler Linehttps://practicaldermatology.com/news/neauvia-scores-ce-marking-under-the-european-unions-new-mdr-for-facial-dermal-filler-line/2461564/Neauvia scored CE marking under the European Union’s new MDR (Medical Device Regulation) for its range of facial dermal fillers products, making it the first medical aesthetics business to receive such certification in Europe. The new regulation aims to create ‘a robus
- Dermalogica Launches New Course on Treating Melanin-Rich Skinhttps://practicaldermatology.com/news/dermalogica-launches-new-course-on-treating-melanin-rich-skin/2461545/In a move to address under-representation in the professional skin care industry’s training curricula regarding melanin-rich skin tones (specifically those categorized as Fitzpatrick levels IV-VI), Dermalogica announced it is launching “Treating Melanin-Rich Skin.” <
- Escient Pharmaceuticals Receives FDA IND Clearance to Start Phase 1 Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-receives-fda-ind-clearance-to-start-phase-1-study-of-ep262/2461542/The FDA has cleared Escient Pharmaceuticals’ investigational new drug (IND) application for EP262. The clearance allows the Escient to initiate a Phase 1 first-in-human study for the company’s second drug candidate to be advanced into clinical development. EP262 is a first-i
- Mount Sinai Physician Promises $5 Million Bequest to Support the Kimberly and Eric J. Waldman Department of Dermatologyhttps://practicaldermatology.com/news/mount-sinai-physician-promises-5-million-bequest-to-support-the-kimberly-and-eric-j-waldman-department-of-dermatology/2461536/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai received a $5 million bequest promised by Kenneth L. Edelson, MD, Clinical Professor of Dermatology. This gift represents Dr. Edelson’s commitment to advancing dermatolo
- Game On: Top Derm Video Game Boosts Clinical Decision Making Among Seasoned Doctorshttps://practicaldermatology.com/news/game-on-top-derm-video-game-boosts-clinical-decision-making-among-seasoned-doctors/2461534/Medical video games increase the competence and clinical decision-making of practicing physicians, a new study by Level Ex shows. Substantial research has demonstrated video-game-based medical training’s effectiveness in the short-term. These studies primarily focused on medi